Anogenital Contact Dermatitis in Spain: A REIDAC Study of Patients Undergoing Patch Testing in 2019-2024.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Grau-Pérez Mercè, Mercader-García Pedro, Giménez-Arnau Ana María, Sanz-Sánchez Tatiana, Ninet Violeta Zaragoza, Guijarro Susana Córdoba, Miquel Francisco Javier Miquel, Salvador Juan Francisco Silvestre, González-Pérez Ricardo, González Inmaculada Ruíz, Baldrich Esther Serra, Carrascosa José Manuel, de Frutos Francisco Javier Ortiz, Serna Mercedes Rodríguez, Ortega María Elena Gatica, Suárez Carmen Paredes, Triviño Francisco José Navarro, Chicharro Pablo, Andreu Marta, Gilo Araceli Sánchez, Pereyra Rodríguez José Juan, Nieto María Antonia Pastor, Melé-Ninot Gemma, Guillén Paloma Sánchez-Pedreño, de la Fuente Enrique Gómez, Elosua-González Marta, Munera-Campos Mónica, Romero Fátima Tous, Descalzo Miguel Ángel, Borrego Leopoldo
Аннотация
OBJECTIVES: To describe the most common diagnoses and update relevant allergens in patients with anogenital lesions referred for patch testing.
METHODS: We analysed patients who underwent patch testing within REIDAC from 2019 to 2024. Patients were classified into three groups: (G1) exclusively anogenital lesions, (G2) no anogenital involvement and (G3) both anogenital and non-anogenital lesions. Sensitisation and relevance were assessed.
RESULTS: Among 18 291 patients, 116 (0.6%) had exclusively anogenital lesions, 17 576 (96.1%) had no anogenital involvement and 599 (3.3%) had both. G1 patients were more likely to have at least one positive reaction (91.4%), a current relevant reaction (53.4%, diagnosed with allergic contact dermatitis, ACD) and to be polysensitised compared to other groups (p < 0.001). 14.5% of anogenital ACD identified cases were not identified by the Spanish baseline series. Fragrances, preservatives, topical anaesthetics and steroids were the leading relevant allergens. Benzisothiazolinone, sodium metabisulfite and propolis emerged as new sensitisers.
CONCLUSION: ACD was highly prevalent among patients with anogenital lesions referred for patch testing. The threshold for patch testing in these patients may need reconsideration.